GuidelineNature reviews. Cardiology2025
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice.
Guideline in Nature reviews. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Comparison of 3 Dual Single-Pill Combinations for Blood Pressure Lowering: A Secondary Analysis of an International Randomized Trial.Circulation · 2026Article
- Mineralocorticoid Receptor Blockade Mitigates Loop Diuretic-Exacerbated Plasma Volume Contraction and Target-Organ Fibrosis in Angiotensin II-Induced Hypertension.International journal of molecular sciences · 2026Article
- Analysis of Circadian Blood Pressure Patterns and Their Clinical, Metabolic, and Structural Correlates in Newly Diagnosed Hypertensive Patients.Biomedicines · 2026Article
- Endogenous and exogenous determinants of sex differences in blood pressure.NPJ cardiovascular health · 2026Review
- Renal Denervation for Uncontrolled Hypertension: A Measurement-First, Program-Based Approach.Journal of clinical medicine · 2026Review
- Investigating the risk factors of sleep disturbances following percutaneous coronary intervention in patients with coronary artery disease: a case-control study.Sleep & breathing = Schlaf & Atmung · 2026Article
- Analysis of epidemiological characteristics and prognosis based on 1,343 cases of aortic dissection from a regional single center.Frontiers in cardiovascular medicine · 2026Article
- Differences in clinical characteristics and cardiovascular disease risk prediction among Chinese women with polycystic ovary syndrome phenotypes: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Hypertension in 2025: are we ready for bold precision public health approaches worldwide?Nature reviews. Cardiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is the most prevalent modifiable risk factor for cardiovascular disease and for cardiovascular and all-cause mortality globally. Suboptimal control of elevated blood pressure places a substantial burden on health-care systems worldwide. Several factors contribute to this suboptimal control, such as limited awareness of hypertension, lack of appropriate diagnosis and poor control of blood pressure among those with a diagnosis. These factors can be due to patient non-adherence to treatment, inertia among health-care professionals and low uptake and implementation of clinical guideline recommendations. From 2003 to 2018, the European Society of Hypertension and the European Society of Cardiology jointly published four sets of guidelines on hypertension. However, the two societies released separate guidelines on hypertension in 2023 and 2024, respectively. These two sets of European guidelines agree on most recommendations, but some differences have been identified. In this Expert Recommendation, we highlight the key consensus recommendations from the two guidelines; compare differing approaches to the definition, classification, diagnosis and treatment of hypertension; and aim to help health-care professionals in their decision-making to improve the management of hypertension and to reduce the burden of hypertension-associated outcomes and premature deaths.
Indexed as
Identifiers
40691360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.